PMID- 35968500
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220816
IS  - 1875-8630 (Electronic)
IS  - 0278-0240 (Print)
IS  - 0278-0240 (Linking)
VI  - 2022
DP  - 2022
TI  - Hepatic Steatosis Index and the Risk of Type 2 Diabetes Mellitus in China: 
      Insights from a General Population-Based Cohort Study.
PG  - 3150380
LID - 10.1155/2022/3150380 [doi]
LID - 3150380
AB  - PURPOSE: In the Chinese population, we looked at the relationship between the 
      hepatic steatosis index (HSI) and the risk of type 2 diabetes mellitus (T2DM). 
      METHODS: To evaluate the association between HSI and the risk of T2DM, Cox 
      regression models were employed. Hazard ratios (HR) and 95 percent confidence 
      intervals (CI) were computed. A stratified analysis with interaction testing was 
      also carried out. Additionally, we evaluated the incremental predictive value of 
      the HSI over the established risk factors using the C-statistic, the IDI, and the 
      NRI. RESULTS: During a median follow-up period of 2.97 years, 433 (1.97%) 
      participants developed new-onset T2DM. The smoothing curve fit plot showed a 
      positive correlation between HSI and the risk of T2DM. After adjusting for all 
      noncollinear variables, the risk of T2DM increased by 62% for every 1 standard 
      deviation (SD) increase in HSI. Subgroup analysis indicated that higher HSI 
      levels were associated with a higher risk of T2DM in those aged < 40 years. The 
      addition of HSI enhanced the reclassification and discrimination of established 
      risk factors, with an IDI of 0.027 and an NRI of 0.348 (both P < 0.001). 
      CONCLUSION: Our findings suggest that an elevated HSI is substantially associated 
      with a greater risk of T2DM in the Chinese population. HSI has the potential to 
      be an available and supplementary monitoring method for the management of T2DM 
      risk stratification in the Chinese population.
CI  - Copyright (c) 2022 Xintian Cai et al.
FAU - Cai, Xintian
AU  - Cai X
AUID- ORCID: 0000-0003-3172-1540
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Gao, Jing
AU  - Gao J
AD  - Research and Education Center of Xinjiang Uygur Autonomous Region People's 
      Hospital, Urumqi, Xinjiang, China.
FAU - Liu, Shasha
AU  - Liu S
AUID- ORCID: 0000-0002-7166-3034
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Wang, Mengru
AU  - Wang M
AUID- ORCID: 0000-0003-1450-2063
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Hu, Junli
AU  - Hu J
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Hong, Jing
AU  - Hong J
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Zhu, Qing
AU  - Zhu Q
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Tuerxun, Guzailinuer
AU  - Tuerxun G
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Dang, Yujie
AU  - Dang Y
AUID- ORCID: 0000-0003-0051-0783
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
FAU - Li, Nanfang
AU  - Li N
AUID- ORCID: 0000-0003-1505-8566
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, 
      Urumqi, Xinjiang, China.
LA  - eng
SI  - Dryad/10.5061/dryad.ft8750v
PT  - Journal Article
DEP - 20220803
PL  - United States
TA  - Dis Markers
JT  - Disease markers
JID - 8604127
SB  - IM
MH  - China/epidemiology
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Humans
MH  - Proportional Hazards Models
MH  - Risk Factors
PMC - PMC9365599
COIS- The authors stated that none of them had competing interests.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/17 06:00
PMCR- 2022/08/03
CRDT- 2022/08/15 04:15
PHST- 2022/02/23 00:00 [received]
PHST- 2022/07/27 00:00 [accepted]
PHST- 2022/08/15 04:15 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/08/03 00:00 [pmc-release]
AID - 10.1155/2022/3150380 [doi]
PST - epublish
SO  - Dis Markers. 2022 Aug 3;2022:3150380. doi: 10.1155/2022/3150380. eCollection 
      2022.